Using the monoclonal antibody Nimotuzumab in treating patients with squamous cell carcinoma of head and neck in advanced stages.

Trial Profile

Using the monoclonal antibody Nimotuzumab in treating patients with squamous cell carcinoma of head and neck in advanced stages.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin; Fluorouracil
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by Cuban Clinical Trial Registry.
    • 06 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top